CN101573343A - 抑制人免疫缺陷病毒的6-取代的嘧啶 - Google Patents
抑制人免疫缺陷病毒的6-取代的嘧啶 Download PDFInfo
- Publication number
- CN101573343A CN101573343A CNA2007800489938A CN200780048993A CN101573343A CN 101573343 A CN101573343 A CN 101573343A CN A2007800489938 A CNA2007800489938 A CN A2007800489938A CN 200780048993 A CN200780048993 A CN 200780048993A CN 101573343 A CN101573343 A CN 101573343A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- compound
- amino
- cyano group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
化合物编号 | IIIB | pSI(IIIB) | L100I+K103N | K103N+Y181C | Y181C | MDR |
1 | 8.46 | 3.26 | 6.94 | 7.71 | 7.96 | 5.75 |
2 | 8.44 | 3.56 | 7.12 | 7.15 | 7.74 | 4.95 |
3 | 8.14 | >3.54 | 7.02 | 6.58 | 6.98 | 5.53 |
4 | 8.51 | 3.63 | 7.99 | 7.86 | 5.55 | |
5 | 8.80 | 3.94 | 7.60 | 8.36 | 8.20 | 5.85 |
6 | 8.05 | >3.44 | 7.39 | 7.70 | 5.73 | |
7 | 8.38 | >3.78 | 7.75 | 7.78 | 5.63 | |
8 | 8.26 | >3.66 | 7.07 | 7.50 | 7.73 | 5.09 |
10 | 8.55 | 3.62 | 8.32 | 7.97 | 8.46 | 6.25 |
化合物编号 | IIIB | pSI(IIIB) | L100I+K103N | K103N+Y181C | Y181C | MDR |
11 | 8.74 | 3.63 | 8.20 | 7.72 | 8.39 | 6.16 |
12 | 8.62 | 3.51 | 6.50 | 6.78 | 7.28 | 5.57 |
13 | 8.54 | 3.50 | 7.20 | 7.68 | 7.79 | 5.59 |
14 | 8.52 | 3.22 | 7.00 | 7.76 | 7.85 | 5.67 |
15 | 8.54 | 3.59 | 7.42 | 7.86 | 7.89 | 5.55 |
16 | 8.54 | 3.60 | 7.06 | 7.61 | 7.60 | 5.64 |
17 | 7.80 | 2.70 | 6.41 | 7.04 | 7.01 | 5.56 |
18 | 9.05 | 4.05 | 7.48 | 7.79 | 8.06 | 6.33 |
19 | 8.48 | 3.50 | 6.83 | 6.97 | 7.68 | 5.32 |
20 | 8.46 | 3.36 | 6.33 | 6.96 | 6.99 | 5.30 |
21 | 8.47 | 3.44 | 7.16 | 7.71 | 7.73 | 5.70 |
22 | 7.93 | 3.25 | 6.35 | 7.02 | 7.09 | 5.50 |
23 | 8.80 | 3.78 | 6.98 | 7.78 | 7.72 | 5.67 |
24 | 9.16 | 4.09 | 7.31 | 7.84 | 8.14 | 5.75 |
25 | 7.63 | 2.02 | 7.30 | 7.03 | 5.75 | |
26 | 8.43 | 3.67 | 8.07 | 7.62 | 5.57 | |
27 | 8.42 | 3.76 | 8.51 | 7.79 | 5.93 | |
28 | 8.68 | 3.67 | 7.27 | 7.82 | 7.81 | 5.68 |
29 | 7.70 | 2.47 | 6.66 | 7.01 | 7.06 | 5.67 |
30 | 8.55 | 3.74 | 7.56 | 7.89 | 7.69 | 5.80 |
31 | 8.41 | 3.60 | 7.13 | 7.71 | 7.48 | 5.48 |
32 | 8.50 | >3.90 | 7.20 | 7.50 | 7.60 | 6.40 |
33 | 8.40 | 3.70 | 7.10 | 8.00 | 7.70 | 6.20 |
34 | 8.40 | 3.40 | 7.90 | 8.40 | 8.00 | 6.30 |
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06127325.6 | 2006-12-29 | ||
EP06127325 | 2006-12-29 | ||
PCT/EP2007/064605 WO2008080964A1 (en) | 2006-12-29 | 2007-12-28 | Hiv inhibiting 6-substituted pyrimidines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101573343A true CN101573343A (zh) | 2009-11-04 |
CN101573343B CN101573343B (zh) | 2016-02-24 |
Family
ID=39283877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780048993.8A Active CN101573343B (zh) | 2006-12-29 | 2007-12-28 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9006243B2 (zh) |
EP (1) | EP2114901B1 (zh) |
JP (1) | JP5185283B2 (zh) |
KR (1) | KR20090094073A (zh) |
CN (1) | CN101573343B (zh) |
AU (1) | AU2007341227C1 (zh) |
BR (1) | BRPI0720858B8 (zh) |
CA (1) | CA2674178C (zh) |
DK (1) | DK2114901T3 (zh) |
EA (1) | EA020772B1 (zh) |
ES (1) | ES2470570T3 (zh) |
MX (1) | MX2009007005A (zh) |
WO (1) | WO2008080964A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102260215A (zh) * | 2011-05-13 | 2011-11-30 | 复旦大学 | 一种二芳基嘧啶类衍生物及其制备方法和用途 |
CN102718720A (zh) * | 2012-07-04 | 2012-10-10 | 宁波九胜创新医药科技有限公司 | 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414A (zh) * | 2012-07-04 | 2012-10-17 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
AU2005288864B2 (en) | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
CN101027288B (zh) | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
BRPI0607811B8 (pt) * | 2005-02-18 | 2021-05-25 | Janssen R & D Ireland | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
MY160734A (en) | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
NZ710636A (en) | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法 |
ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
KR20150119012A (ko) | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
JP6531958B2 (ja) | 2017-04-17 | 2019-06-19 | 千住金属工業株式会社 | フラックス組成物及びソルダペースト組成物 |
JP7331579B2 (ja) | 2018-09-28 | 2023-08-23 | 荒川化学工業株式会社 | 鉛フリーはんだフラックス、鉛フリーソルダペースト |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
CZ154398A3 (cs) | 1995-11-23 | 1998-08-12 | Janssen Pharmaceutica N.V. | Pevné směsi cyklodextrinů připravené vytlačováním taveniny |
NO311614B1 (no) | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
ATE232521T1 (de) * | 1998-03-27 | 2003-02-15 | Janssen Pharmaceutica Nv | Hiv hemmende pyrimidin derivate |
EP0945447A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
BRPI9915552B8 (pt) | 1998-11-10 | 2021-05-25 | Janssen Pharmaceutica Nv | pirimidinas inibidoras da reprodução do hiv |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
EP1282606B1 (en) * | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
US20030105090A1 (en) | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
MXPA05005146A (es) | 2002-11-15 | 2005-07-22 | Tibotec Pharm Ltd | Indolpiridinio sustituido como compuestos antiinfecciosos. |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7531548B2 (en) * | 2004-09-30 | 2009-05-12 | Tibotec Pharmaceuticals Ltd | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
AU2005288864B2 (en) | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
CN101027288B (zh) * | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
CN101107234B (zh) * | 2005-01-27 | 2013-06-19 | 泰博特克药品有限公司 | 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
CN101410394B (zh) * | 2006-03-30 | 2012-02-08 | 泰博特克药品有限公司 | 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
-
2007
- 2007-12-28 BR BRPI0720858A patent/BRPI0720858B8/pt not_active IP Right Cessation
- 2007-12-28 CN CN200780048993.8A patent/CN101573343B/zh active Active
- 2007-12-28 EP EP20070858201 patent/EP2114901B1/en active Active
- 2007-12-28 MX MX2009007005A patent/MX2009007005A/es active IP Right Grant
- 2007-12-28 JP JP2009543476A patent/JP5185283B2/ja active Active
- 2007-12-28 CA CA2674178A patent/CA2674178C/en active Active
- 2007-12-28 AU AU2007341227A patent/AU2007341227C1/en not_active Ceased
- 2007-12-28 WO PCT/EP2007/064605 patent/WO2008080964A1/en active Application Filing
- 2007-12-28 EA EA200970655A patent/EA020772B1/ru not_active IP Right Cessation
- 2007-12-28 KR KR1020097009722A patent/KR20090094073A/ko not_active Application Discontinuation
- 2007-12-28 US US12/521,189 patent/US9006243B2/en active Active
- 2007-12-28 ES ES07858201.2T patent/ES2470570T3/es active Active
- 2007-12-28 DK DK07858201T patent/DK2114901T3/da active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102260215A (zh) * | 2011-05-13 | 2011-11-30 | 复旦大学 | 一种二芳基嘧啶类衍生物及其制备方法和用途 |
CN102718720A (zh) * | 2012-07-04 | 2012-10-10 | 宁波九胜创新医药科技有限公司 | 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414A (zh) * | 2012-07-04 | 2012-10-17 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414B (zh) * | 2012-07-04 | 2014-11-26 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2010514735A (ja) | 2010-05-06 |
AU2007341227B2 (en) | 2013-04-18 |
EP2114901B1 (en) | 2014-04-09 |
BRPI0720858B1 (pt) | 2020-01-21 |
US20100016317A1 (en) | 2010-01-21 |
KR20090094073A (ko) | 2009-09-03 |
JP5185283B2 (ja) | 2013-04-17 |
WO2008080964A1 (en) | 2008-07-10 |
EP2114901A1 (en) | 2009-11-11 |
EA020772B1 (ru) | 2015-01-30 |
BRPI0720858B8 (pt) | 2021-05-25 |
CA2674178C (en) | 2015-11-10 |
US9006243B2 (en) | 2015-04-14 |
ES2470570T3 (es) | 2014-06-24 |
EA200970655A1 (ru) | 2009-12-30 |
DK2114901T3 (da) | 2014-06-30 |
CA2674178A1 (en) | 2008-07-10 |
AU2007341227A1 (en) | 2008-07-10 |
CN101573343B (zh) | 2016-02-24 |
MX2009007005A (es) | 2009-07-09 |
BRPI0720858A2 (pt) | 2014-07-01 |
AU2007341227C1 (en) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101573343B (zh) | 抑制人免疫缺陷病毒的6-取代的嘧啶 | |
CN101573342A (zh) | 抑制hiv的5,6-取代的嘧啶类化合物 | |
CN101405283B (zh) | Hiv抑制性5-酰氨基取代的嘧啶类化合物 | |
ES2353725T3 (es) | Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el vih. | |
EP2675803A1 (en) | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | |
AU2012218004A1 (en) | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: IRELAND JANSSEN R + D COMPANY Free format text: FORMER OWNER: JANSSEN R + D IRELAND Effective date: 20150724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: The Irish Village Applicant after: JANSSEN R&D IRELAND Address before: The Irish Village Applicant before: TIBOTEC PHARMACEUTICALS Address after: The Irish Village Applicant after: TIBOTEC PHARMACEUTICALS Address before: The Irish Village Applicant before: TIBOTEC PHARMACEUTICALS Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: Free format text: CORRECT: APPLICANT; FROM: TIBOTEC NV TO: TIBOTEC PHARM LTD. Free format text: CORRECT: APPLICANT; FROM: TIBOTEC PHARM LTD. TO: JANSSEN R + D IRELAND |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150724 Address after: The Irish Village Applicant after: JANSSEN R&D IRELAND Address before: The Irish Village Applicant before: JANSSEN R&D IRELAND |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |